PKC? as Metabolic Immune Checkpoint Candidate

Researchers in Innsbruck are working on improving adoptive cell therapies to make tumor treatments more effective. A key discovery reveals that the enzyme PKC plays a regulatory role in cancer immunity. Inhibiting this enzyme enables T cells to recognize and combat tumor cells more effectively. Using advanced technologies, the team is investigating how these modified T cells perform in preclinical models and whether they can enhance treatment efficacy in the long term. This research aims to develop new approaches for personalized cancer therapies, particularly for non-small cell lung cancer (NSCLC). The project is a combination of clinically highly relevant basic research and a promising translational immunotherapy approach. The ultimate goal of the project is the sustainable improvement of clinical treatment options for patients with advanced lung cancer, for whom there are currently insufficient treatment options.